FDA approves Genentech arthritis drug for rare disorder in children
SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a drug made by Genentech for a rare form of arthritis in children, the company said Tuesday.
Genentech, a subsidiary of Swiss drug maker Roche, announced the approval of Actemra (tocilizumab) for polyarticular juvenile idiopathic arthritis in children ages 2 years and older, either alone or combined with the generic drug methotrexate.
"Polyarticular juvenile idiopathic arthritis is a rare, debilitating condition in children that worsens over time," Genentech chief medical officer and head of global product development Hal Barron said. "We are pleased to offer Actemra to doctors and patients ages 2 years and older as an important medicine to help improve signs and symptoms of this often painful disease."
Revamped Adidas personal care collection for men, women hits market
NEW YORK — A revamped Adidas personal care range has hit the market, reflecting the athletic energy of today’s man and the confidence of the modern woman.
The new collection for men includes body sprays, deodorants, antiperspirants, and hair and body washes. With bold graphics and striking colors, the entire packaging redesign was executed with the dynamic modern Adidas man in mind.
New to the range is Dynamic Pulse, a clean and aromatic fragrance with peppermint. Existing scents include Deep Energy, Pure Game and Extra Fresh
The new range for women features three signature scents available as a body spray and deodorant body fragrance. Inspired by feminine shapes, the new Adidas for Women packaging is designed for women’s daily life and sporty moments with colorful, bold graphics for a fun, feminine twist.
The Adidas personal care retails for $3.47 each and is available at Walmart stores nationwide.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Family Dollar supply chain exec exits company
MATTHEWS, N.C. — Family Dollar Stores on Monday announced Charles Gibson, EVP supply chain, will leave the company to pursue other interests effective April 30.
“Charlie has overseen the growth and development of our supply chain network and has been a valued part of our team,” stated Howard Levine, Family Dollar chairman and CEO. “We appreciate the contributions Charlie has made to the company’s success, and we wish him all the best in his future endeavors.”
Family Dollar reported an earnings increase of 2.7% for its most recent quarter. But profits missed Wall Street estimates.
"A shift to lower margin items is what drove the slight miss in earnings," wrote Peter Pham in a Fool report published the day before the announcement. "In recent months, Family Dollar started to focus on selling high-turnover merchandise, such as cigarettes and other tobacco products, soft drinks, magazines, gift cards, etc. These items bring shoppers in stores more frequently, but carry lower margins than other merchandise, such as apparel."